Merrimack works with a quality set of partners and collaborators to ensure the best expertise and technologies are applied to our discovery and development efforts.

DYAX Corp. Cambridge, MA
DYAX Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. Dyax is a leader in the use of phage display technology to produce high-affinity antibodies against targets of interest. Merrimack has formed a collaboration with Dyax under which Dyax is using its proprietary technologies to generate antibodies against Merrimack's targets which Merrimack will evaluate for commercial development.

GTC Biotherapeutics Framingham, MA
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. Merrimack is engaged with GTC in a strategic partnership for the production of MM-093 for clinical development and testing.

Selexis SA Geneva, Switzerland
Selexis SA is a biotechnology company dedicated to the development of innovative technologies and expert services related to recombinant protein manufacturing. Through this collaboration, Merrimack accesses Selexis’ SURE Cell Line Development (SM) to develop mammalian cell lines for the research, development and manufacturing of Merrimack’s therapeutic candidates.

About: Suppliers

Merrimack is committed towards working with quality suppliers that support Merrimack's growth through innovation, improving productivity, establishing efficiencies and reducing costs.

Suppliers

Purchas Order Terms and Conditions

[ back to top ]